U.S. Markets closed

Wider-than-Expected Loss at Endocyte

Zacks Equity Research

Endocyte, Inc. (ECYT) reported first quarter 2013 net loss per share of 11 cents, wider than the Zacks Consensus Estimate of a loss of 5 cents but narrower than  the year-ago loss of 27 cents.

First quarter 2013 revenues were $14.5 million compared with no revenues in the first quarter 2012. Revenues comprised solely of collaboration revenues. Revenues surpassed the Zacks Consensus Estimate of $14 million.

In the reported quarter, research and development expenses were $12.3 million, up 92.2%. The company’s effort to develop its pipeline was primarily responsible for the increase. In the reported quarter, general and administrative (G&A) expenses jumped 103.2% to $6.3 million. The increase was attributable to establishing commercial capability. An increase in compensation expenses was also responsible for pushing G&A costs up.

In 2012, Endocyte submitted a marketing authorization application (MAA) seeking approval for vintafolide for platinum-resistant ovarian cancer. The company is also seeking EU approval for a folate-targeted molecular imaging agent, etarfolatide. Both were granted orphan drug status in the EU in 2012. The company expects a decision from the European Commission on both candidates in the fourth quarter of 2013.

Endocyte and its partner Merck & Co. Inc. (MRK) will initiate a phase II randomized trial on vintafolide in folate receptor-positive triple negative breast cancer in the fourth quarter of 2013.

For its folate-targeted tubulysin therapeutic, Endocyte will file an investigational new drug (IND) application and initiate a study in the third quarter of 2013.

Endocyte maintained its cash, cash equivalents and investments guidance in the range of $145 - $160 million as on Dec 31, 2013.

Endocyte carries a Zacks Rank #4 (Sell). Currently, companies like Lannett Company, Inc. (LCI) and Catalyst Pharmaceutical Partners Inc. (CPRX)  look more attractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on ECYT

Read the Full Research Report on MRK

Read the Full Research Report on CPRX

Read the Full Research Report on LCI

Zacks Investment Research

More From Zacks.com